blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3733663

EP3733663 - 1-[6-[[4-(PHENYLAMINO)-6-QUINAZOLINYL]OXY]-3-AZABICYCLO[3.1.1]HEPT-3-YL]-2-PROPEN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS IRREVERSIBLE INHIBITORS OF PAN-HER TYROSINE KINASE FOR THE TREATMENT OF CANCER [Right-click to bookmark this link]
Former [2020/45]QUINAZOLINE DERIVATIVE AND USE THEREOF
[2023/10]
StatusNo opposition filed within time limit
Status updated on  22.03.2024
Database last updated on 19.07.2024
FormerThe patent has been granted
Status updated on  14.04.2023
FormerGrant of patent is intended
Status updated on  21.02.2023
FormerRequest for examination was made
Status updated on  02.10.2020
FormerThe international publication has been made
Status updated on  29.06.2019
Most recent event   Tooltip24.05.2024Lapse of the patent in a contracting state
New state(s): IT		published on 26.06.2024  [2024/26]
Applicant(s)For all designated states
CHENGDU JINRUI FOUNDATION BIOTECH CO., LTD.
Suite 2004, 20/F, East Hope Center
333 N Yizhou Avenue
High-tech District
Chengdu, Sichuan 610000 / CN
[2023/09]
Former [2022/11]For all designated states
Shenzhen Jinrui Foundation Biotech Co., Ltd
A2402, Innovation Plaza
2007, Pingshan Avenue
Liulian Community, Pingshan Street
Pingshan District
Shenzhen, Guangdong / CN
For all designated states
Medshine Discovery Inc.
Room 218, No. 9 Gaoxin Road
Jiangbei New District
Nanjing, Jiangsu 210032 / CN
Former [2021/51]For all designated states
Medshine Discovery Inc.
Room 218, No. 9 Gaoxin Road
Jiangbei New District
Nanjing, Jiangsu 210032 / CN
For all designated states
Shenzhen Jinrui Foundation Biotech Co., Ltd
A2402, Innovation Plaza
2007, Pingshan Avenue
Liulian Community, Pingshan Street
Pingshan District
Shenzhen, Guangdong / CN
Former [2020/45]For all designated states
Medshine Discovery Inc.
Room 218, No. 9 Gaoxin Road
Jiangbei New District
Nanjing, Jiangsu 210032 / CN
Inventor(s)01 / CHEN, Kevin X
288 Futezhong Road, Pudong New Area
Shanghai 200131 / CN
02 / WEI, XiaWei
State Key Lab Of Biotherapy, Sichuan University
No. 17, The Third Part Renmin South Road
Chengdu, Sichuan 610041 / CN
03 / ZHANG, Li
288 Futezhong Road, Pudong New Area
Shanghai 200131 / CN
04 / YU, Yanxin
288 Futezhong Road, Pudong New Area
Shanghai 200131 / CN
05 / ZHOU, Kai
288 Futezhong Road, Pudong New Area
Shanghai 200131 / CN
06 / HU, Boyu
288 Futezhong Road, Pudong New Area
Shanghai 200131 / CN
07 / CHEN, Zhaoguo
288 Futezhong Road, Pudong New Area
Shanghai 200131 / CN
08 / ZHANG, Huiyu
288 Futezhong Road, Pudong New Area
Shanghai 200131 / CN
09 / CHEN, Shuhui
288 Futezhong Road, Pudong New Area
Shanghai 200131 / CN
 [2020/45]
Representative(s)De Clercq & Partners
Edgard Gevaertdreef 10a
9830 Sint-Martens-Latem / BE
[2020/45]
Application number, filing date18890726.519.12.2018
[2020/45]
WO2018CN122016
Priority number, dateCN20171137675719.12.2017         Original published format: CN201711376757
CN20181022574219.03.2018         Original published format: CN201810225742
CN20181057652905.06.2018         Original published format: CN201810576529
[2020/45]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019120213
Date:27.06.2019
Language:ZH
[2019/26]
Type: A1 Application with search report 
No.:EP3733663
Date:04.11.2020
Language:EN
[2020/45]
Type: B1 Patent specification 
No.:EP3733663
Date:17.05.2023
Language:EN
[2023/20]
Search report(s)International search report - published on:CN27.06.2019
(Supplementary) European search report - dispatched on:EP27.07.2021
ClassificationIPC:C07D403/12, C07D413/14, C07D401/14, C07D405/14, C07D403/14, C07D409/14, C07D471/04, C07D451/02, C07D498/04, A61K31/517, A61P35/00
[2021/34]
CPC:
C07D401/14 (EP); C07D239/94 (US); A61P35/00 (EP);
C07D401/12 (EP,US); C07D403/12 (EP,US); C07D403/14 (EP);
C07D405/12 (US); C07D405/14 (EP,US); C07D409/12 (US);
C07D409/14 (EP,US); C07D413/12 (US); C07D413/14 (EP,US);
C07D451/02 (EP); C07D471/04 (EP); C07D471/08 (EP);
C07D498/04 (EP,US) (-)
Former IPC [2020/45]C07D403/12, C07D405/14, A61K31/517, C07D409/14, C07D413/14, C07D498/04, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/45]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:1-[6-[[4-(PHENYLAMINO)-6-QUINAZOLINYL]OXY]-3-AZABICYCLO[3.1.1]HEPT-3-YL]-2-PROPEN-1-ON-DERIVATE UND ÄHNLICHE VERBINDUNGEN ALS IRREVERSIBLE INHIBITOREN DER PAN-HER TYROSINE KINASE ZUR BEHANDLUNG VON KREBS[2023/10]
English:1-[6-[[4-(PHENYLAMINO)-6-QUINAZOLINYL]OXY]-3-AZABICYCLO[3.1.1]HEPT-3-YL]-2-PROPEN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS IRREVERSIBLE INHIBITORS OF PAN-HER TYROSINE KINASE FOR THE TREATMENT OF CANCER[2023/10]
French:DÉRIVÉS DE 1-[6-[[4-(PHÉNYLAMINO)-6-QUINAZOLINYL]OXY]-3-AZABICYCLO[3.1.1]HEPT-3-YL]-2-PROPEN-1-ONE ET COMPOSÉS SIMILAIRES EN TANT QU'INHIBITEURS IRRÉVERSIBLES DE TYROSINE KINASE PAN-HER POUR LE TRAITEMENT DU CANCER[2023/10]
Former [2020/45]CHINAZOLINDERIVAT UND VERWENDUNG DAVON
Former [2020/45]QUINAZOLINE DERIVATIVE AND USE THEREOF
Former [2020/45]DÉRIVÉ DE QUINAZOLINE ET SON UTILISATION
Entry into regional phase03.07.2020Translation filed 
03.07.2020National basic fee paid 
03.07.2020Search fee paid 
03.07.2020Designation fee(s) paid 
03.07.2020Examination fee paid 
Examination procedure03.07.2020Examination requested  [2020/45]
20.01.2022Amendment by applicant (claims and/or description)
22.02.2023Communication of intention to grant the patent
31.03.2023Fee for grant paid
31.03.2023Fee for publishing/printing paid
31.03.2023Receipt of the translation of the claim(s)
Opposition(s)20.02.2024No opposition filed within time limit [2024/17]
Fees paidRenewal fee
17.12.2020Renewal fee patent year 03
30.11.2021Renewal fee patent year 04
24.11.2022Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT17.05.2023
CZ17.05.2023
DK17.05.2023
EE17.05.2023
ES17.05.2023
FI17.05.2023
HR17.05.2023
IT17.05.2023
LT17.05.2023
LV17.05.2023
NL17.05.2023
PL17.05.2023
RO17.05.2023
RS17.05.2023
SE17.05.2023
SI17.05.2023
SK17.05.2023
SM17.05.2023
NO17.08.2023
GR18.08.2023
IS17.09.2023
PT18.09.2023
[2024/26]
Former [2024/25]AT17.05.2023
CZ17.05.2023
DK17.05.2023
EE17.05.2023
ES17.05.2023
FI17.05.2023
HR17.05.2023
LT17.05.2023
LV17.05.2023
NL17.05.2023
PL17.05.2023
RO17.05.2023
RS17.05.2023
SE17.05.2023
SI17.05.2023
SK17.05.2023
SM17.05.2023
NO17.08.2023
GR18.08.2023
IS17.09.2023
PT18.09.2023
Former [2024/10]AT17.05.2023
CZ17.05.2023
DK17.05.2023
EE17.05.2023
ES17.05.2023
FI17.05.2023
HR17.05.2023
LT17.05.2023
LV17.05.2023
NL17.05.2023
PL17.05.2023
RO17.05.2023
RS17.05.2023
SE17.05.2023
SK17.05.2023
SM17.05.2023
NO17.08.2023
GR18.08.2023
IS17.09.2023
PT18.09.2023
Former [2024/08]AT17.05.2023
ES17.05.2023
FI17.05.2023
HR17.05.2023
LT17.05.2023
LV17.05.2023
NL17.05.2023
PL17.05.2023
RS17.05.2023
SE17.05.2023
SK17.05.2023
SM17.05.2023
NO17.08.2023
GR18.08.2023
IS17.09.2023
PT18.09.2023
Former [2024/03]AT17.05.2023
ES17.05.2023
FI17.05.2023
HR17.05.2023
LT17.05.2023
LV17.05.2023
NL17.05.2023
PL17.05.2023
RS17.05.2023
SE17.05.2023
NO17.08.2023
GR18.08.2023
IS17.09.2023
PT18.09.2023
Former [2024/01]AT17.05.2023
ES17.05.2023
HR17.05.2023
LT17.05.2023
LV17.05.2023
NL17.05.2023
PL17.05.2023
RS17.05.2023
SE17.05.2023
NO17.08.2023
GR18.08.2023
IS17.09.2023
PT18.09.2023
Former [2023/51]AT17.05.2023
ES17.05.2023
HR17.05.2023
NL17.05.2023
PL17.05.2023
RS17.05.2023
SE17.05.2023
NO17.08.2023
GR18.08.2023
IS17.09.2023
PT18.09.2023
Former [2023/50]AT17.05.2023
ES17.05.2023
NL17.05.2023
PL17.05.2023
SE17.05.2023
NO17.08.2023
GR18.08.2023
IS17.09.2023
PT18.09.2023
Former [2023/48]AT17.05.2023
ES17.05.2023
NL17.05.2023
SE17.05.2023
NO17.08.2023
PT18.09.2023
Former [2023/46]ES17.05.2023
PT18.09.2023
Documents cited:Search[A]WO2015154725  (SICHUAN HAISCO PHARMACEUTICAL CO LTD [CN]) [A] 1-15* claims 1, 3, 8, 9 *;
 [A]WO2017107985  (XUANZHU PHARMA CO LTD [CN]) [A] 1-15 * page 1, line 17 - page 2, line 10 * * claims 1, 20 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.